helenachristy

1
MILLION HEALTH PHARMACEUTICALS

• Mabtas 100mg - Anticancer drugs view uses, side
  effects and price MHP

2
DESCRIPTION

• Mabtas 100mg is a anticancer medicine which
  prevents the growth and spread of cancer cells in
  the body. 
• Mabtas 100mg injection also indicated for the
  treatment of Non- Hodgkins lymphoma or chronic
  lymphocytic and with combination with another
  anticancer drugs like methotrexate is used for
  rheumatoid arthritis symptoms in adult
  treatment. 
• Mabtas 100mg with steroid regimen combination is
  given for the treatment of some rare disorders
  which cause blood vessels and other tissues
  inflammation in the body.

3
INDICATION

• Mabtas 100mg injection and hyaluronidase human
  injection are given alone or combination with
  another drugs to treat certain types of
  non-Hodgkin's lymphoma and chronic lymphocytic
  leukemia (cancer start in WBC). 
• Mabtas 100mg injection is also used with
  methotrexate (Otrexup, Rasuvo, Xatmep, others)
  for the treatment rheumatoid arthritis symptoms
  in adults that have been already treated with a
  some type of regimen known as tumor necrosis
  factor (TNF) inhibitor. Mabtas 100mg is a type in
  a classification of drugs called monoclonal
  antibodies.

4
NON HODGKINS LYMPHOMA
5
PHARMACODYNAMIC

• new type of "targeted" cancer treatment and an
  integral part of the body's immune system.
  Naturally the body build antibodies in along with
  to an antigen which has entered the body and
  attach to the antigen for destruction by the
  immune system. An essential cells only aimed by
  monoclonal antibiotics, they may leads to less
  toxicity to healthy cell and it is usually
  treatment recommended only for cancers in which
  antigens (and the respective antibodies) have
  been already identified. Mabtas works by linking
  to the CD20 antigen on normal and malignant
  B-cells. Hence the body's essential immune
  security are initiated to attack and kill the
  marked B-cells. Stem cells i.eyoung cells in the
  bone marrow which will grow into the various cell
  types and do not have the CD20 antigen. After
  treatment,CD20 antigen allows healthy B-cells to
  multiply

6
PRODUCT DETAILS

• Brand MabtasIngredients Rituximab Strength
  100mg Manufactured Intas pharmaceuticalsPack
  age injection

7
PHARMACOKINETICS

• ABSORPTIONNot availableDISTRIBUTIONvolume of
  distribution is 3.1 LMETABOLISMMabtas 100mg
  injection metabolized by human antimurine
  antibody production.EXCRETIONnot available The
  half life of NHL is 22 days and for RA is 18.0
  days, GPA and microscopic polyangitis is 23 days

8
DOSAGE MANAGEMENT

• Mabtas 100mg is recommended to administer only
  through intravenous infusion not by IV push or
  bolus.
• ADMINISTRATIONTake an Mabtas 100 mg
  injection amount and diluted to final
  concentration of 1 mg/ml upto 4 mg/ml as infusion
  (containing either 0.9 Nacl or 5 dextrose in
  water). Invert gently the bag and mix the
  solution. Dispose unused drug left in vial. 
• OVERDOSAGE If the patients had high dose
  of Mabtas 100mg then seek immediately to the
  emergency department or poison control help line.
  Please consult the doctor for further
  clarification.

9
PRECAUTIONS

• Allgeric condition against Mabtas 100mg or any
  other medication informs your doctorWhile
  using Mabtas 100mg injection do not take any
  vaccination or immunization without taking advice
  from doctors. Avoid use of Mabtas 100mg if you
  are pregnant. It will harm the baby unborn, while
  using 
• Mabtas 100mg use correct birth control to prevent
  pregnancy and for at least 2 weeks after your
  treatment ends. 
• Mabtas 100mg injection may affect the ability to
  have children in women.

10
SIDE EFFECTS

• COMMON EFFECTS
• fever and chills (flu lik symptoms)LESS COMMON
  SIDE EFFECTS
• Weakness nausea headache cough dyspnae
  pharyngitis

11
DRUG INTERACTION

• Mabtas 100mg drug interaction has limited data is
  available at present. Combination with
  fludarabine or cyclophosphamide has no effects in
  pharmacokinetics in CLL patients. Combination
  with methotrexate had no effects in
  pharmacokinetics.

12
CONTRAINDICATIONS

• Hypersensitivity or murine proteins. Active
  severe infectons in rheumatoid arthritis
  Uncontrolled cardiac disease.

13
PREGNANCY

• CategoryC animal studies reproduction shown an
  adverse effect on the fetus. The drug has no
  sufficient and well controlled studies in humans,
  using in pregnant women benefits by warrant use
  of the drug.

14
LACTATION

• Mabtas 100mg injection excreted into human milk
  is unknown. Due to the drug belongs to large
  protein molecule, no information is available.
  Women should not breast feed during Mabtas
  100mg treatment and 12 months following last dose.

15
STORAGE

• Store at 2C 3CUse the drug before expiry
  dateProtected from direct sunlightDo not freeze
  or shake.Keep away from the childernsDiscard
  the unused drug by asking the advice from doctor
  or pharmacist.

16
MISSED DOSE

• Store at 2C 3CUse the drug before expiry
  dateProtected from direct sunlightDo not freeze
  or shake.Keep away from the childernsDiscard
  the unused drug by asking the advice from doctor
  or pharmacist.

17
CONTACT US

• EMAIL ID
• millionhealthpharmaceuticals_at_gmail.com
• PHONE NO
• 91-9940472902
• WEBSITE URL https//millionpharma.com/mabt
  as-100mg.php